|Awarded On||February 21, 2018|
|Title||Molecular mechanisms of anthracycline response in cardiomyocytes and link to genetic susceptibility to cardiotoxicity in long-term childhood cancer survivors|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michelle Hildebrandt|
|Cancer Sites||All Sites|
Anthracyclines are highly effective chemotherapeutic drugs that improve survival for many types of childhood cancers, but are known to cause irreversible and progressive cardiac damage that often manifests decades following treatment. These late cardiotoxic effects are a serious complication of cancer treatment and are the third most common cause of premature death in long-term survivors of childhood cancer. The underlying mechanisms for the development of late cardiotoxicity remain unclear due to lack of human model systems to explore the effect of anthracyclines on the cardiomyocyte. With the emergence of pluripotent stem cell (iPSC)-derived cardiomyocytes as a model system, this study was...